Abstract CT034: Dose expansion results of single agent ficerafusp alfa (BCA101), a bifunctional EGFR/TGFβ inhibitor in patients with metastatic or advanced cutaneous squamous cell carcinoma (CSCC)
Year: 2025
Type: conference-abstract
Source: Cancer Research
Institutions: MUSC Hollings Cancer Center, Memorial Sloan Kettering Cancer Center, University of Southern California, Dana-Farber Cancer Institute, Moffitt Cancer Center, Cleveland Clinic, The University of Texas MD Anderson Cancer Center, Calvary Mater Newcastle Hospital, Peter MacCallum Cancer Centre, University of California, Los Angeles
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4409822425